Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA

通过 siRNA 纳米颗粒递送来治疗 Ras 通路

基本信息

  • 批准号:
    7982953
  • 负责人:
  • 金额:
    $ 16.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

Project 2: Therapeutic Targeting of the Ras Pathway by Nanoparticle Delivery of siRNA Three types of nanoparticles, i.e. LPD, LCP and PRINT, will be used to deliver siRNA to lung cancer cells in a genetically engineered mouse (GEM) model (Kim, co-PI). LPD is a self-assembled, core/membrane nanoparticle, the unique feature of which is the high density ofthe surface grafted PEG chains. Previous work by Huang (co-PI) has shown that LPD accumulates in xenografted human lung tumors at the level of 60-80 % injected dose per g of tissue with minimal uptake by liver and spleen. Three daily i.v. injections of LPD containing siRNA effectively silenced the tumor target gene expression. LCP is similar in structure to LPD, but the core is replaced with calcium phosphate amorphous nanoprecipltate that dissolves in the endosomal acidic pH to release its cargo and swells and bursts the endosomes. The PRINT (DeSimone, co-1) are topdown manufactured nanoparticles In which any carrier and cargo materials can be readily loaded. Dr. DeSimone has shown that siRNA can be successfully loaded in PRINT and delivered to tumor cells for gene silencing. A salient feature of the project is the KRas driven lung cancer GEM. sIRNAs designed against Ras and Ras effector pathways will be tested and delivered as therapeutics. This is particularly significant, because Ras is considered an undruggable target by conventional medicinal chemistry approaches. Furthermore, gemcitabine mono (or di-) phosphate (GMP or GDP), metabolites of gemcitabine will be formulated in LCP nanoparticles and delivered to the tumor cells by itself or together with siRNA. This is a novel approach that takes advantage of the large cargo capacity of these nanoparticles. The project is milestone driven in that by the end of the year 3, at least one nanoparticle formulation will be identified for therapy, pharmacokinetics and toxicity studies In GEM. The formulation should be ready for detailed characterization and toxicity studies in collaboration with Nanotechnology Characterization Lab at NCI for further translational development
项目2:通过纳米粒传递siRNA靶向RAS通路 三种类型的纳米粒子,即LPD,LCP和Print,将被用来在基因工程小鼠(GEM)模型(Kim,co-PI)中将siRNA传递到肺癌细胞。LPD是一种自组装的核/膜纳米粒子,其独特之处在于表面接枝了高密度的聚乙二醇链。Huang(co-Pi)以前的工作表明,LPD在移植的人肺肿瘤中累积在每克组织60%-80%的注射剂量水平,肝脏和脾摄取最少。每日三次静脉注射。注射含有siRNA的LPD可有效沉默肿瘤靶基因的表达。LCP在结构上与LPD相似,但核心被无定形纳米聚磷酸钙取代,该纳米聚磷酸钙溶解在内体酸性pH中释放其货物,并膨胀和破裂内体。印刷品(DeSimone,co-1)是自上而下制造的纳米颗粒,任何载体和货物材料都可以很容易地装载在其中。德西蒙博士已经证明,siRNA可以被成功地装载到印刷品中,并被运送到肿瘤细胞中,以实现基因沉默。该项目的一个显著特点是KRAS驱动的肺癌宝石。针对RAS和RAS效应通路设计的siRNAs将作为治疗药物进行测试和交付。这一点特别重要,因为RAS被传统的药物化学方法认为是一个不可用药的靶点。 此外,吉西他滨的代谢物吉西他滨一(或二)磷酸(GMP或GDP)将被制成LCP纳米颗粒,并单独或与siRNA一起输送到肿瘤细胞。这是一种新的方法,利用了这些纳米颗粒的大载货能力。该项目具有里程碑意义,因为到第三年年底,将确定至少一种纳米颗粒配方,用于GEM的治疗、药代动力学和毒性研究。该配方应准备好与NCI纳米技术表征实验室合作进行详细的表征和毒性研究 进一步的翻译开发

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leaf Huang其他文献

Leaf Huang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leaf Huang', 18)}}的其他基金

Nano Approaches to Modulate Host Cell Response for Cancer Therapy
调节宿主细胞反应以进行癌症治疗的纳米方法
  • 批准号:
    8960618
  • 财政年份:
    2015
  • 资助金额:
    $ 16.04万
  • 项目类别:
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
项目 1:维莫非尼耐药黑色素瘤的纳米疗法
  • 批准号:
    8960620
  • 财政年份:
    2015
  • 资助金额:
    $ 16.04万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8731891
  • 财政年份:
    2013
  • 资助金额:
    $ 16.04万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8613538
  • 财政年份:
    2013
  • 资助金额:
    $ 16.04万
  • 项目类别:
Therapeutic Targeting of the Ras Pathway By Nanoparticle Delivery of siRNA
通过 siRNA 纳米颗粒递送来治疗 Ras 通路
  • 批准号:
    8540374
  • 财政年份:
    2013
  • 资助金额:
    $ 16.04万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8882415
  • 财政年份:
    2013
  • 资助金额:
    $ 16.04万
  • 项目类别:
Nanocrystals for the Treatment of Multidrug Resistance in Cancer
用于治疗癌症多药耐药性的纳米晶体
  • 批准号:
    8680176
  • 财政年份:
    2011
  • 资助金额:
    $ 16.04万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米颗粒
  • 批准号:
    8212466
  • 财政年份:
    2010
  • 资助金额:
    $ 16.04万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米粒子
  • 批准号:
    8606435
  • 财政年份:
    2010
  • 资助金额:
    $ 16.04万
  • 项目类别:
Novel nanoparticles for siRNA delivery
用于 siRNA 递送的新型纳米颗粒
  • 批准号:
    8053486
  • 财政年份:
    2010
  • 资助金额:
    $ 16.04万
  • 项目类别:

相似海外基金

Uncovering colorectal cancer etiology and biology by integrating proteomics with other omics data
通过将蛋白质组学与其他组学数据相结合,揭示结直肠癌的病因学和生物学
  • 批准号:
    10585424
  • 财政年份:
    2023
  • 资助金额:
    $ 16.04万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10446594
  • 财政年份:
    2022
  • 资助金额:
    $ 16.04万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10647719
  • 财政年份:
    2022
  • 资助金额:
    $ 16.04万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10307055
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10224955
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10201868
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10527364
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
Life course body fatness and physical activity, and ovarian cancer etiology
生命历程身体脂肪和体力活动以及卵巢癌病因
  • 批准号:
    435914
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
    Operating Grants
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10093129
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    9885673
  • 财政年份:
    2020
  • 资助金额:
    $ 16.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了